Novartis: Lutathera NETTER-1 Data Shows Improvement In PFS - Quick Facts

Shutterstock photo

(RTTNews.com) - Novartis ( NVS ) reported a new analysis of Lutathera (lutetium Lu 177 dotatate) NETTER-1 data examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden. The company said the data showed that Lutathera treatment resulted in significant improvement in progression free survival regardless of the extent of baseline liver tumor burden, elevated alkaline phosphatase liver enzyme or presence of large lesion in patients with progressive midgut neuroendocrine tumors compared to octreotide LAR alone.

Lutathera is the first Peptide Receptor Radionuclide Therapy to receive regulatory registration, with approval by the European Commission in September 2017 and by the US FDA in January 2018.

Jonathan Strosberg, Principle Investigator of the NETTER-1 study, said: "These new data provide hope for these patients and reinforce the potential benefit of Lutathera treatment in this population."

Read the original article on RTTNews (http://www.rttnews.com/2945117/novartis-lutathera-netter-1-data-shows-improvement-in-pfs-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: Stocks , Commodities
Referenced Symbols: NVS

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?